Rigel Pharmaceuticals Stock Analysis

Rigel Stock Analysis Notes

About 69.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Rigel Pharmaceuticals had 1:10 split on the 27th of June 2024. Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Rigel Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 165 people. To find out more about Rigel Pharmaceuticals contact Raul Rodriguez at 650 624 1100 or learn more at https://www.rigel.com.

Rigel Pharmaceuticals Investment Alerts

Rigel Pharmaceuticals Upcoming and Recent Events

Rigel Largest EPS Surprises

View All Earnings Estimates

Rigel Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Rigel Pharmaceuticals Thematic Classifications

Rigel Stock Institutional Investors

Note, although Rigel Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Rigel Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 366.91 M.

Rigel Profitablity

The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.

Management Efficiency

Rigel Pharmaceuticals has return on total asset (ROA) of 0.1075 % which means that it generated a profit of $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.13 this year. Return On Capital Employed is expected to rise to 0.25 this year. At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Non Currrent Assets Other will most likely fall to about 1.2 M.

Technical Drivers

As of the 25th of March, Rigel Pharmaceuticals holds the Coefficient Of Variation of 2193.64, risk adjusted performance of 0.0491, and Semi Deviation of 3.6. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rigel Pharmaceuticals, as well as the relationship between them. Please check Rigel Pharmaceuticals downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Rigel Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 18.9 per share. Given that Rigel Pharmaceuticals has jensen alpha of 0.2625, we recommend you to check out Rigel Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Rigel Pharmaceuticals Price Movement Analysis

Rigel Pharmaceuticals Insider Trading Activities

Rigel Pharmaceuticals Outstanding Bonds

Rigel Pharmaceuticals Predictive Daily Indicators

Rigel Pharmaceuticals Corporate Filings

Rigel Pharmaceuticals Forecast Models

Rigel Pharmaceuticals' time-series forecasting models are one of many Rigel Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rigel Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Rigel Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rigel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rigel Pharmaceuticals. By using and applying Rigel Stock analysis, traders can create a robust methodology for identifying Rigel entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rigel analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rigel analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Rigel Pharmaceuticals stock analysis indicators help investors evaluate how Rigel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rigel Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rigel Pharmaceuticals stock analysis, traders can identify Rigel Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.